EyePoint Pharmaceuticals Q3 2026 Earnings Call Transcript
EyePoint Pharmaceuticals reported disappointing Phase 3 wet AMD trial results, leading them to discontinue the program and reduce their workforce by 53%. The company is now focusing all resources on Duravu for diabetic macular edema (DME), which has shown promising Phase 2 data and a different biological profile from wet AMD. EyePoint ended Q3 2026 with $118 million in cash, expected to fund operations into late Q3 2027, and anticipates top-line results for the DME COMO and CAPRI trials in early Q4 2027.
EyePoint Pharmaceuticals stock pivots to DME after wet AMD setback
EyePoint Pharmaceuticals is shifting its development focus to diabetic macular edema (DME) after its wet age-related macular degeneration (AMD) trials, LUGANO and LUCIA, failed to meet their primary endpoints. The company's two Phase III DME studies, COMO and CAPRI, are fully enrolled and are now presented as the main clinical catalysts for its investigational treatment, DURAVYU. This strategic pivot is supported by positive Phase II VERONA study results, which showed DURAVYU matching Eylea on visual acuity and requiring fewer rescue injections in DME patients.
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
EyePoint, Inc. announced its participation in several upcoming investor conferences and scientific meetings in November and December 2026. The investor conferences will feature fireside chats, while the scientific meetings, such as Eyenovate at FLORetina and FLORetina-ICOOR 2026 Congress, will include presentations on the LUCIA Pivotal Phase 3 Trial results for EYP-1901 in wet AMD and updates on the COMO/CAPRI trials for diabetic macular edema (DME). The company is focused on developing DURAVYU™ (EYP-1901) for serious retinal diseases.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors. The investigation follows significant drops in EyePoint's stock price after the announcement of disappointing Phase 3 clinical trial results for DURAVYU™ (vorolanib intravitreal insert) in treating wet age-related macular degeneration (wet AMD), leading to the termination of the clinical program and workforce reductions. Investors are encouraged to contact the firm for more information.
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
EyePoint, Inc. announced it will host a conference call and live webcast on November 12, 2026, at 8:30 a.m. ET to report its third-quarter 2026 financial results and discuss recent corporate developments. The company is focused on developing and commercializing innovative therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU™, currently in Phase 3 trials for diabetic macular edema (DME). Investors and media can access the event through a registration link or the company's website.
EyePoint Pharmaceuticals, Inc. (EYPT) latest stock news and headlines
This Yahoo Finance article provides a curated list of recent news and headlines related to EyePoint Pharmaceuticals, Inc. (EYPT). It highlights various reports concerning the company's stock performance, earnings estimates, drug trial results for DURAVYU™ in wet AMD, and strategic prioritization announcements. The content indicates a significant drop in stock value following trial setbacks and workforce reductions.
EyePoint Pharmaceuticals Inc (PV3B.DU) Seasonal returns chart
The article presents a seasonal returns chart for EyePoint Pharmaceuticals Inc (PV3B.DU), showing the average monthly price return from 2024 to 2026. As of the latest update, the stock was trading at 0.3060 EUR, down 0.65%. The chart helps investors understand the stock's historical performance trends throughout the year.
EyePoint Pharmaceuticals Inc (PV3B.DU) Seasonal Returns Chart - Yahoo Finance
This article presents the seasonal returns chart for EyePoint Pharmaceuticals Inc (PV3B.DU) on Yahoo Finance. It displays the average monthly price return for various periods from 2024 to 2026, alongside current market data for the stock.
EyePoint Pharmaceuticals, Inc. (EYPT) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for EyePoint Pharmaceuticals, Inc. (EYPT). It displays the average monthly price return for the company's stock between 2016 and 2026, alongside current trading data. The information includes real-time and overnight prices, allowing investors to gauge historical performance trends.
EyePoint: DME Upside Remains, But Financing Could Consume Most Of It (Rating Downgrade)
EyePoint's rating is downgraded from a speculative Strong Buy to a Hold due to LUCIA’s failure and pending clarity on cash runway and financing. While DURAVYU’s DME opportunity offers an estimated $1.2 billion conditional DCF, significant clinical and regulatory risks persist. The company needs to substantially lower cash consumption to reach DME readouts without further financing, as unfavorable terms could dilute most economic value for new investors.
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky, LLP is investigating EyePoint Pharmaceuticals (NASDAQ: EYPT) for potential securities law violations after the company's shares fell approximately 80% following the disclosure that its Phase 3 LUCIA trial for DURAVYU missed its primary endpoint in wet age-related macular degeneration. Shareholders who incurred losses due to this announcement may have legal rights and are encouraged to contact the firm for a no-cost evaluation of their potential recovery. The investigation focuses on whether EyePoint made misleading statements regarding its DURAVYU wet AMD program.
EyePoint Pharmaceuticals Inc (EYPT) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength
This article provides a profile of EyePoint Pharmaceuticals Inc (EYPT), a biopharmaceutical company specializing in treatments for eye disorders. It includes key company facts such as its sector, industry, employee count, and answers to frequently asked questions regarding its market capitalization, 52-week high and low prices, current and previous day's stock prices, PE ratio, Price-to-Book ratio, and 50-day moving average. The company offers FDA-approved sustained-release treatments under several brands.
EyePoint Pharmaceuticals Inc (EYPT) Earnings, Actual EPS, EPS Estimates & Results
This article provides an overview of EyePoint Pharmaceuticals Inc (EYPT) earnings, including upcoming estimates and historical results. It highlights that the company's Q3 '26 earnings report is scheduled for November 4, pre-market, with an estimated EPS of -$0.93 and estimated revenue of $0.23M. The historical data shows that EYPT has missed EPS estimates for the past four reported quarters, from Q3 '25 to Q2 '26.
EyePoint, Inc. (EYPT) stock price, news, quote and history
EyePoint, Inc. (EYPT) recently experienced a significant stock price drop of over 85% following the failure of a pivotal wet age-related macular degeneration (AMD) trial for its lead product candidate, DURAVYU. This setback has led to a 53% workforce reduction and a strategic reprioritization for the biotechnology company. Despite the recent challenges, EyePoint continues to develop therapeutics for serious retinal diseases using its proprietary bioerodible Durasert E technology.
JPMorgan Downgrades EyePoint Pharmaceuticals to Underweight From Neutral
JPMorgan has downgraded EyePoint Pharmaceuticals from a "Neutral" to an "Underweight" rating. This indicates a decreased positive outlook on the company's stock performance by the investment bank. Further details on the reasons for the downgrade were not provided in this snippet.
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
SueWallSt.com has announced an investigation into EyePoint Pharmaceuticals (NASDAQ: EYPT) following an approximate 80% stock value drop. This occurred after the Company's Phase 3 LUCIA trial for DURAVYU failed to meet its primary endpoint in wet age-related macular degeneration. The investigation focuses on potentially misleading statements regarding the trial design and FDA alignment, encouraging affected shareholders to submit their loss details.
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
Levi & Korsinsky is investigating EyePoint Pharmaceuticals (EYPT) for potential securities law violations after its shares dropped nearly 80% due to the disappointing Phase 3 LUCIA trial results for DURAVYU. The drug failed to meet its primary endpoint in treating wet age-related macular degeneration. Investors who suffered losses are encouraged to submit their information for a no-cost review of their potential legal rights.
EyePoint halves workforce and ends Phase III trial early after endpoint miss
EyePoint Pharmaceuticals announced significant job cuts and the early termination of its Phase III clinical trial for duravyu in wet age-related macular degeneration (wAMD) after the candidate failed to meet its primary endpoint. The company will reduce its workforce by 53% to save $30 million annually and pivot its focus to developing duravyu for diabetic macular oedema (DME), where it previously had positive Phase II results. This news led to an over 80% drop in EyePoint's stock value.
EyePoint Pharma shares plunge 80% after Phase 3 trial failure for DURAVYU in eye disease
EyePoint Pharmaceuticals' stock plummeted nearly 80% after its DURAVYU drug failed to meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration, despite showing some treatment burden reduction. A legal firm is now investigating potential securities law violations related to the trial results. This event provides context for investors interested in the health sector.
EyePoint to halve workforce after experimental drug fails second late-stage trial
EyePoint (EYPT.O) announced it would cut approximately 53% of its workforce and cease studies of its experimental drug Duravyu for wet age-related macular degeneration after the drug failed a second late-stage trial. The drug, which was tested against Regeneron's Eylea, did not prove as effective in preserving eyesight. EyePoint plans to focus on developing Duravyu for diabetic macular edema, expecting late-stage trial results in late 2027, and anticipates saving about $30 million annually from these changes.
EyePoint Stock Sinks 82% After Key Eye Drug Fails and Staff Is Slashed. Strategy Shift’s Success Is ‘Pretty Debatable.’
EyePoint Pharmaceuticals experienced an 82% stock drop after its lead eye drug failed a primary trial goal. This failure has led the company to cut its workforce in half, raising questions about the success of its strategic shift. The biopharmaceutical company is now in crisis as it navigates these significant setbacks.
Watertown biotech halves workforce after two late-stage trials miss their goals
EyePoint Inc. is significantly reducing its workforce by 53% after two of its late-stage trials for wet AMD failed to meet their goals. The Watertown-based biotech company will now shift its focus to developing treatments for diabetic macular edema. This decision follows the discontinuation of the failed wet AMD trials.
EyePoint Pharmaceuticals to Cut 53% of Workforce After Eye Disease Drug Trial Setback
EyePoint Pharmaceuticals announced plans to reduce its workforce by 53% following a setback in a drug trial for an eye disease. The company also intends to end further development of the drug. This move comes as a response to the trial's outcome, impacting a significant portion of its employees.
EyePoint Announces Strategic Prioritization
EyePoint, Inc. announced a strategic prioritization to reduce operating expenses and focus on its late-stage program for DURAVYU™ in diabetic macular edema (DME). This decision follows the Phase 3 LUCIA study for DURAVYU in wet AMD, which did not meet its primary endpoint, leading to a workforce reduction of approximately 53% and early conclusion of wet AMD trials. The company will now prioritize the DME program, with Phase 3 data expected in Q4 2027, aiming to preserve capital and maximize shareholder value.
EyePoint Cuts 53% of Workforce After LUCIA Trial
EyePoint is reducing its workforce by 53% following the failure of its Phase 3 LUCIA trial for wet AMD to meet its primary endpoint. This restructuring aims to save approximately $30 million annually, with the company shifting focus to its DURAVYU program for diabetic macular edema, with pivotal Phase 3 results anticipated in Q4 2027. The company expects $9 million in separation charges and reported $118 million in cash and short-term investments as of September 30.
EyePoint cuts headcount, shifts priorities after another Duravyu AMD miss
EyePoint Pharmaceuticals' shares plummeted after its Duravyu wet AMD trial failed to meet its primary endpoint, leading the company to reduce its workforce by 53% and cut the wet AMD program to save $30 million. The drugmaker will reallocate capital and prioritize its diabetic macular edema (DME) pipeline, with phase 3 results expected in Q4 2027, expressing confidence based on prior phase 2 success in DME.
EyePoint Pharmaceuticals stock closed at EUR 2.76, up 3.76 percent
EyePoint Pharmaceuticals stock closed at EUR 2.76 in Frankfurt, marking a 3.76 percent increase. Despite a significant GAAP net loss of USD 94.47 million for the quarter ended June 30, 2026, and a broad range of analyst views, the company's clinical pipeline, particularly DURAVYU's Phase 3 trials, remains central to its long-term investment case. EyePoint is estimated to report third-quarter results on November 4, 2026.
Insiders Sold EyePoint At US$15.75, Meanwhile Stock Sits Near US$2.99
EyePoint, Inc. (NASDAQ:EYPT) insiders sold US$410k worth of stock over the last year at an average price of US$15.75, which is significantly higher than the current share price of US$2.99. While there has been more selling than buying overall in the last year, a recent insider purchase of US$52k by an Independent Director suggests some confidence in the company. Despite the selling, the fact that sales occurred at a much higher price point mitigates some negative sentiment, but overall insider ownership remains low at 0.9%.
Here's Why You Should Add EYPT Stock to Your Portfolio Now
EyePoint Pharmaceuticals (EYPT) is a clinical-stage biotechnology company developing treatments for retinal diseases, with its lead candidate, Duravyu, showing promise despite mixed initial results. The company is evaluating Duravyu for wet AMD and diabetic macular edema, with key data readouts expected in Q4 2026 and Q4 2027. Despite a significant stock drop, EyePoint holds a Zacks Rank #2 (Buy) due to narrowing loss per share estimates, and the article suggests it as a potential addition to an investment portfolio.
EyePoint Pharmaceuticals stock fell 3.08 percent as LUCIA nears
EyePoint Pharmaceuticals (EYPT) stock dropped 3.08% to $3.15 after its DURAVYU drug missed a primary endpoint in the LUGANO trial, though it showed a 42% reduction in treatment burden. The company's Q2 revenue beat estimates but EPS missed, and attention is now focused on the upcoming LUCIA Phase 3 study results and a potential FDA filing in mid-2027. Analyst targets remain significantly higher than the current stock price, reflecting potential value from a successful LUCIA trial.
EyePoint Pharmaceuticals stock holds at USD 3.25 after loss
EyePoint Pharmaceuticals (EYPT) closed at USD 3.25 on Nasdaq after reporting a significant drop in second-quarter revenue to USD 507,000, down from USD 5.33 million in the prior year. Despite a GAAP net loss of USD 94.47 million, 13 analysts still maintain a "Buy" rating for the stock, with an average 12-month price target of USD 25.91, highlighting the potential upside tied to its late-stage eye-drug pipeline. The company's valuation is heavily influenced by the progress of its investigational sustained-delivery treatment, DURAVYU, for serious retinal diseases.
PV3B Stock Price and Chart — HAN:PV3B
This article provides detailed information on EyePoint, Inc. (PV3B) stock traded on the Hannover Stock Exchange, including key financial stats, upcoming earnings, company info, and analyst insights. It highlights the company's biopharmaceutical focus on eye disorder treatments and includes various trading ideas and forecasts from the TradingView community.
JonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
JonesTrading analyst Debanjana Chatterjee has reiterated a Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $20.00. This recommendation comes despite the company reporting a significant GAAP net loss of $94.47 million in its latest quarter, alongside reduced revenue compared to the previous year. Corporate insider sentiment for EYPT is neutral, with a recent sale of shares by the CMO.
EyePoint Pharmaceuticals Inc (PV3B.MU) Analyst Insights, Price Targets & Recommendations - Yahoo Finance
This article provides analyst insights, price targets, and recommendations for EyePoint Pharmaceuticals Inc (PV3B.MU). It details recent upgrades and downgrades from various financial institutions, indicating shifts in analyst sentiment towards the company. The stock closed at 3.1000 EUR, down 3.73%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Pomerantz LLP is investigating potential claims against EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors. This investigation follows a significant stock price drop after EyePoint announced that its pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) did not meet its primary endpoint for treating wet age-related macular degeneration. The firm is examining whether EyePoint and its officers engaged in securities fraud or unlawful business practices.
EyePoint Pharmaceuticals stock holds near its yearly range
EyePoint Pharmaceuticals (EYPT) stock traded near its yearly range on September 23, 2026, with its latest reported period being key for valuation. The company, which develops sustained-delivery medicines for retinal diseases, is a small-cap biotechnology stock where clinical progress, regulatory milestones, and financing needs are central valuation factors. Investors should focus on reported operating figures to assess development risk and the time available to reach clinical milestones rather than daily trading fluctuations.
EyePoint at Morgan Stanley conference: duravyu path stays open By Investing.com
EyePoint Pharmaceuticals (EYPT) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, discussing both challenges and ongoing optimism for its lead wet age-related macular degeneration (wet AMD) program, DURAVYU. Despite missing the primary non-inferiority endpoint in the LUGANO trial, the company highlighted strong secondary results, a clean safety profile, and a potential path to approval if the LUCIA study proves positive. EyePoint also emphasized its diabetic macular edema (DME) program, with data expected in Q4 2027, and stated it has sufficient cash reserves into Q4 2027.
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT)
This article highlights bullish sentiments from analysts regarding three healthcare companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT), and Abbott Laboratories (ABT). H.C. Wainwright reiterated a Buy rating for BridgeBio Pharma with a $120.00 price target, while Citi maintained a Buy rating for EyePoint Pharmaceuticals with a $17.00 price target, and also a Buy rating for Abbott Laboratories with a $125.00 price target. The article details analyst consensus ratings and average price targets for each company, indicating potential upsides.
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20
TD Cowen downgraded EyePoint Pharmaceuticals (EYPT) from a Buy rating to Hold and significantly adjusted its price target from $20 to $4. The company currently holds an average overweight rating with a mean price target of $34.55. Access to the full details requires a premium subscription.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO
EyePoint (EYPT) recently experienced a sharp fair value reset from US$40.54 to US$25.91, following a split in analyst sentiment due to the LUGANO Phase 3 primary endpoint miss. Despite some bullish takes on positive secondary endpoints and safety data, several firms have downgraded the stock, citing execution risk and regulatory uncertainty for Duravyu. The narrative now focuses on how future trial results, like the LUCIA study, will impact the company's long-term potential and fair value.
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney
Kirby McInerney LLP is investigating potential securities fraud claims against EyePoint Pharmaceuticals (NASDAQ: EYPT) following a significant drop in its stock price. This comes after EyePoint announced that its DURAVYU drug missed its primary endpoint in the Phase 3 LUGANO wet AMD trial, contradicting earlier confident statements from the company's CEO. Investors who purchased EyePoint securities are encouraged to contact the law firm to learn more about their rights.
Eyepoint Pharmaceuticals topline Lugano trial results spark momentum for sustained release TKI in wet AMD
Eyepoint Pharmaceuticals announced promising topline results from its Lugano trial for sustained release tyrosine kinase inhibitors (TKIs) in treating wet age-related macular degeneration (AMD). President and CEO Jay S. Duker, M.D., highlighted the potential of long-acting TKI therapies to improve patient outcomes and reduce treatment burden. This announcement follows earlier disclosures regarding the pivotal Phase 3 LUGANO trial of DURAVYU and the company's Q2 2026 financial results, further contextualizing its pipeline development in ophthalmology.
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky, LLP has announced a securities investigation into EyePoint Pharmaceuticals (NASDAQ: EYPT) following a significant drop in its stock price. This decline occurred after the company's DURAVYU drug failed to meet its primary endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. The firm is encouraging investors who suffered losses to submit their information for a potential securities fraud claim.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)
Levi & Korsinsky is investigating potential securities claims against EyePoint Pharmaceuticals (EYPT) after its shares dropped nearly 67% following the failure of its DURAVYU Phase 3 LUGANO trial. The law firm is encouraging shareholders who suffered losses to have their legal rights reviewed, as the company's previous statements about the trial's confidence are under scrutiny. Investors do not incur upfront costs for the review, and eligibility is based on purchase date and documented losses, not current shareholding.
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
Shares of Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) rallied after rival EyePoint Pharmaceuticals (EYPT) reported a setback in its late-stage trial for an eye implant to treat wet age-related macular degeneration. Analysts believe EyePoint's trial failure eases competition for Ocular's similar drug Axpaxli and improves the outlook for 4D Molecular's 4D-150 gene therapy. While EyePoint's stock plummeted, OCUL and FDMT experienced their best trading days in weeks.
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
SueWallSt.com has announced an investigation into EyePoint Pharmaceuticals (NASDAQ: EYPT) following a significant 67% stock drop after its DURAVYU drug failed to meet its primary endpoint in a Phase 3 trial for wet AMD. The firm is inviting investors who suffered losses to submit their information for a potential securities fraud claim, questioning whether EyePoint made misleading statements about the trial's progress. This investigation highlights concerns about the company's prior assurances regarding the drug's potential before disclosing the trial's failure.
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
EyePoint Pharmaceuticals' stock plummeted 70% after its investigational eye treatment, duravyu, failed its primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wAMD). The drug did not show superiority to aflibercept in improving vision, though EyePoint highlighted positive secondary endpoints and an ad hoc analysis. The company now awaits results from a twin trial, Lucia, as competitor Ocular Therapeutix advances its own wAMD candidate.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold"
Royal Bank of Canada downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from "moderate buy" to "hold," and Cantor Fitzgerald also shifted to a neutral rating. This follows the company's DURAVYU trial missing its primary endpoint, leading to a sharp stock decline and concerns about its future regulatory and commercial success. Despite some analysts maintaining "buy" ratings, the consensus among analysts tracked by MarketBeat is now "Hold" with an average price target of $28.11.
EYPT Stock Crashes On Duravyu Data But Catalysts Loom
EyePoint Pharmaceuticals (EYPT) stock initially crashed by 69% after its Phase 3 LUGANO trial for DURAVYU in wet AMD missed its primary vision endpoint on the full dataset. However, an ad hoc analysis, excluding an asymmetric cohort, showed non-inferiority against aflibercept and other strong secondary outcomes, leading to a rebound. Despite a wider Q2 EPS loss, the company has significant cash reserves and upcoming catalysts, including topline data for the LUCIA trial in Q4 2026 and potential NDA submission in 2027.
Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price
Citigroup has significantly cut its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) from $35.00 to $17.00, while still maintaining a "buy" rating, indicating a potential upside of 216.10% from its current price of $5.38. This downgrade follows the failure of the company's LUGANO trial for DURAVYU to meet its primary endpoint and a reported quarterly loss of $1.09 per share, missing consensus estimates. The stock has seen a sharp decline, trading near its one-year low, and analysts' consensus for EYPT is now a "Hold" with an average target of $28.11.